Evidence map›Paper›PMID 25473268›Full record

SynthesisDrug design, development and therapy2014

Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety.

Dongsheng Hong, Zhihai Yang, Shuyin Han, Xingguang Liang, Kuifen Ma, Xingguo Zhang

Open access · goldAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Dongsheng HongDepartment of Pharmacy, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Zhihai YangDepartment of Pharmacy, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Shuyin HanDepartment of Pharmacy, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Xingguang LiangDepartment of Pharmacy, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Kuifen MaDepartment of Pharmacy, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Xingguo ZhangDepartment of Pharmacy, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, People's Republic of China ; College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
Hangzhou First People's Hospital · CNZhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnakinra is the first interleukin-1 inhibitor to be used in clinical practice, and recent evidence showed that interleukin-1 plays a pivotal role in the pathogenesis of adult-onset Still disease (AoSD). However, data concerning efficacy with anakinra use in different clinical trials has not been evaluated, and the overall remission of AoSD with anakinra treatment has not been well defined.

methodsWe conducted a search on Embase, PubMed, and the Cochrane Library for relevant trials. Statistical analyses were conducted to calculate the overall remission rates, odds ratios (OR), and 95% confidence intervals (CI), by using either random effects or fixed effect models according to the heterogeneity.

resultsOf the 273 articles that were identified, 265 were excluded. Eight studies were eligible for inclusion. The overall remission rate and complete remission rate of anakinra in AoSD patients were 81.66% (95% CI: 69.51%-89.69%) and 66.75% (95% CI: 59.94%-75.3%), respectively. Compared with the controls, the use of anakinra was associated with a significant remission in AoSD, with an OR of 0.16 (95% CI: 0.06-0.44, P=0.0005). There were also significant reductions of the dosage of corticosteroid (mean difference =21.19) (95% CI: 13.2-29.18, P<0.0001) from anakinra onset to the latest follow up time. Clinical and laboratory parameters were all improved, and anakinra was well tolerated in patients with AoSD. No evidence of publication bias was observed.

conclusionOur study has shown that anakinra is effective in remitting the manifestations of AoSD, with reduction of the dose of corticosteroid in patients with AoSD. Further, anakinra therapy was not associated with increased risk of adverse events, and it was well tolerated in patients with AoSD. Further research is still recommended to investigate these findings.

Indexed as

Drug-Related Side Effects and Adverse ReactionsInterleukin-1Interleukin 1 Receptor Antagonist ProteinStill's Disease, Adult-OnsetHumansInterleukin-1Interleukin 1 Receptor Antagonist Proteinadverse eventsanakinraAoSDclinical and laboratory parametersefficacyinterleukin-1 inhibitor

Identifiers

PMID25473268
PMCPMC4251663
OpenAlexW2038796481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.